March 17, 2008 - NIR Diagnostics Inc. (TSX Venture: NID), an innovator in the development of handheld healthcare diagnostic devices, announced that it has signed a regional distribution agreement for its portable CO-oximeter device, HemoNIR™, with a European based medical device distributor company. The multi-year agreement stipulates that the Distributor must meet a defined set of sales performance criteria. NIR Diagnostics is currently not disclosing the name of the Distributor pending the completion of negotiations with North American medical device companies also interested in distribution rights to HemoNIR™... NIR Diagnostics' press Release -
Blog Archive
-
▼
2008
(297)
-
▼
April
(50)
- NuRx Pharmaceuticals : Phase I Clinical Trial of F...
- Replidyne Discontinues Phase III Trial
- InterMune : Progress on Pirfenidone in Idiopathic ...
- MedImmune and Infinity : Preclinical Data Highlig...
- Diffusion Pharmaceuticals : patent no. 7,351,844 e...
- Micromet : Phase 1 Clinical Trial with MT110, the ...
- Sorin : approval to market heart-lung machine in J...
- Gene Express : licensing agreement with University...
- Genentech : "AVAiL" Phase III Study of Avastin Plu...
- Spectrum Pharmaceuticals : Preclinical Data Demons...
- Kosan : Phase 2 Trial of Epothilone KOS-1584 in No...
- Infinity Pharmaceuticals' Hedgehog Antagonist Dela...
- Oncolytics Biotech : Dose Escalation in Combinatio...
- Alfacell's ONCONASE : Potential as Radiation Sensi...
- Lilly's ALIMTA : European Approval for Histologica...
- Rosetta Genomics : Agreement With West Coast CLIA ...
- Pharmaxis : CF Trial in Children Returns Positive ...
- MedImmune : Asthma Program with Start of a Phase 2...
- Transave : Study Confirms Anti-Infective ARIKACE E...
- Antisoma and Novartis : phase III lung cancer tria...
- UCB : Phase II results for CDP791 in non-small cel...
- Dinamika : A New Asthma Treatment Introduced by Ru...
- SkyePharma : exclusive License Agreement with Kyor...
- eResearchTechnology, Inc. and nSpire Health, Inc. ...
- Alnylam : ALN-RSV01 in Adult Lung Transplant Pati...
- Critical Therapeutics : Phase I Clinical Trial of ...
- bioMerieux & University of Sunderland : Collaborat...
- TaiGen : Positive Data From the Phase II Study of ...
- Aeolus Pharmaceuticals : AEOL 10150 Protects Lungs...
- AVEO’s Novel Triple VEGF Receptor Inhibitor... Cli...
- Idera Pharmaceuticals : Preclinical Data of its To...
- Kamada : New Orphan Drug Designation by the FDA, f...
- Yale and Asuragen : a microRNA Can Reduce Lung Can...
- Aradigm : Trial of Lung Rx's Inhaled Treprostinil
- KaloBios : Phase 1/2 Trial of Humaneered Monoclona...
- Kamada : Phase III Clinical Trial with Intravenous...
- Cortex : Enrollment in Opiate Induced Respiratory ...
- Actelion and Nippon Shinyaku : pulmonary arterial ...
- Angeion : Medical Graphics Platinum Elite Series P...
- Ceragenix Pharmaceuticals : CeraShield(TM) Coated ...
- NIR Diagnostics : agreement with a European medic...
- Third Wave’s InPlex CF Molecular Test : FDA Clearance
- Celgene : Amrubicin Receives FDA Orphan Drug Desig...
- Lorus : initiation of IND-enabling toxicology stud...
- Poniard Pharmaceuticals : Commercial Manufacturing...
- OXiGENE : Phase II NSCLC Trial of ZYBRESTAT(TM) in...
- Discovery Labs and Chrysalis Technologies : about ...
- MediciNova : Phase II Clinical Trial of MN-221 in ...
- Vertex : Positive Results for VX-770, an Oral Inve...
- Philips : completion of Respironics acquisition
-
▼
April
(50)